CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AtheroGenics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AtheroGenics, Inc.
8995 Westside Parkway
Phone: (678) 336-2500p:678 336-2500 Alpharetta, GA  30009  United States Ticker: AGIXQ AGIXQ
This company ceased filing statements with the SEC on 6/22/2009.
This company is no longer actively traded on any major stock exchange.
Business Summary
AtheroGenics, Inc. (AtheroGenics) is focused on the discovery, development and commercialization of therapeutics for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease. AGI-1067 is the Company’s investigational drug with demonstrated anti-inflammatory and antioxidant properties. AGI-1096 was an antioxidant and selective anti-inflammatory agent to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection. On September 15, 2008 an involuntary petition under Chapter seven of the United States Bankruptcy Code (the Bankruptcy Code) was filed against AtheroGenics by certain holders of its 2008 Notes in the United States Bankruptcy Court for the Northern District of Georgia (the Bankruptcy Court). On April 1, 2009, the Company sold substantially all of its non-cash assets to Crabtree Acquisition Co., LLC as part of the Chapter 11 Proceeding.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/200912/31/2008YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
6726 Unit investment trusts, face-amount certificate offices

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Michael A.Henos 59 1/1/1999 1/1/1994
President, Chief Financial Officer, Secretary Charles A.Deignan 44 4/1/2009 1/1/2007
Director Russell M.Medford 54 4/1/2009 1/1/1993

Business Names
Business Name
AGIXQ
AtheroGenics, Inc.

General Information
Number of Employees: 2 (As of 4/30/2009)
Outstanding Shares: 39,518,492 (As of 6/10/2009)
Shareholders: 72
Stock Exchange: OTC
Federal Tax Id: 582108232
Fax Number: (678) 336-2501
Email Address: investor@atherogenics.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023